Amarin Corporation plc develops and commercializes cardiovascular therapeutics centered on icosapent ethyl, marketed as VASCEPA in the United States and VAZKEPA in Europe. Company news commonly covers product revenue, cash flow, U.S. prescription trends, partner-led international commercialization, and European distribution under an exclusive licensing and supply agreement with Recordati.
Updates also include medical-society guideline discussions, REDUCE-IT analyses, peer-reviewed publications, and scientific meeting presentations on cardiovascular risk reduction, elevated triglycerides, eicosapentaenoic acid, and lipoprotein(a) oxidation.
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
FAQ
What is the current stock price of Amarin (AMRN)?
Amarin (AMRN) last closed at $12.11.
What is the market cap of Amarin (AMRN)?
The market cap of Amarin (AMRN) is approximately $255.8M.